Rnase a peptides, fragments and uses thereof
AssigneeGovernment of the US, as represented by the Secretary, Department of Health and Human Services
InventorsTakeaki Nitto, Kimberly D. Dyer, Meggan Czapiga, Helene F. Rosenberg, Steven J. Siegel
Life of this patent
Estimating the term…
Abstract
The present invention features isolated polypeptides that have bactericidal and angiogenic activities. The invention features isolated polypeptides comprising amino acid sequences of RNase A ribonucleases, fragments and variants thereof, pharmaceutical compositions, and methods for treatment of a subject.
Claims21
An isolated nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule comprising a nucleotide sequence which is at least about 90% identical to the nucleotide sequence of SEQ ID NO:
- 1 or SEQ ID NO:
- 3, or a complement thereof;
- b) a nucleic acid molecule comprising a fragment of at least 15 nucleotides of a nucleic acid comprising the nucleotide sequence of SEQ ID NO:
- 1 or SEQ ID NO:
- 3, or a complement thereof;
- c) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 90% identical to the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 4;
- d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 4;
- wherein the fragment comprises at least 5 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 4;
- and
- e) a nucleic acid molecule which encodes a variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 4;
- wherein the nucleic acid molecule hybridizes to a complement of a nucleic acid molecule comprising SEQ ID NO:
- 1 or SEQ ID NO:
- 3, under stringent conditions.
An isolated polypeptide selected from the group consisting of:
- a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 4, wherein the fragment comprises at least 5 contiguous amino acids of SEQ ID NO:
- 2 or SEQ ID NO:
- 4;
- b) a variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 4, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a complement of a nucleic acid molecule comprising SEQ ID NO:
- 1 or SEQ ID NO:
- 3, under stringent conditions;
- c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 4, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a complement of a nucleic acid molecule comprising SEQ ID NO:
- 1 or SEQ ID NO:
- 3, under stringent conditions;
- d) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 50% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:
- 1 or SEQ ID NO:
- 3;
- and
- e) a polypeptide comprising an amino acid sequence which is at least 30% homologous to the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO:
An antibody that specifically binds Gallus gallus leukocyte RNase A-1 (SEQ ID NO:
- 9).
An antibody that specifically binds Gallus gallus leukocyte RNase A-2 (SEQ ID NO:
- 10).
An isolated polypeptide comprising an amino acid fragment of SEQ ID NO:
- 2 or SEQ ID NO:
- 4. wherein the isolated polypeptide is bactericidal, bacteriostatic, or angiogenic.
11-12. (canceled)
An isolated polypeptide comprisingi
- (i) the amino acid sequence TTRRHFRIT (SEQ ID NO:
- 6), wherein the peptide is bactericidal, bacteriostatic, or angiogenic)
- (ii) the amino acid sequence TRIRTRFHT (SEQ ID NO:
- 11), wherein the peptide is bactericidal, bacteriostatic, or angiogenic;
- (iii) the amino acids T,T,R,R,H,F,R,I,T (SEQ ID NO:
- 6), in any sequence, wherein the peptide is bactericidal, bacteriostatic, or angiogenic;
- (iv) the amino acids T,R,I,R,T,R,F,H,T (SEQ ID NO:
- 11), in any sequence, wherein the peptide is bactericidal, bacteriostatic, or angiogenic;
- (v) the amino acid sequence RYSGNQFNRRVRVGCRG (SEQ ID NO:
- 12), wherein the peptide is bactericidal, bacteriostatic, or angiogenic;
- (vi) the amino acids R,Y,S,G,N,Q,F,N,R,R,V,R,V,G,C,R,G (SEQ ID NO:
- 12), in any sequence, wherein the peptide is bactericidal, bacteriostatic, or angiogenic;
- (vii) an amino acid sequence of RNase A-2 (SEQ ID NO:
- 4), wherein said polypeptide is bactericidal;
- (viii) an amino acid sequence of RNase A-2 (SEQ ID NO:
- 4), wherein said polypeptide is bacteriostatic;
- (ix) an amino acid sequence of RNase A-2 (SEQ ID NO:
- 4), wherein said polypeptide is angiogenic;
- (x) chicken leukocyte RNase A-2 domain II, wherein said domain has the amino acid sequence set forth as SEQ ID NO:
- 6;
- and/or.
- (xi) chicken leukocyte RNase A-2 domain III, wherein said domain has the amino acid sequence set forth as SEQ ID NO:
- 8.
14-31. (canceled)
33-36. (canceled)
38-44. (canceled)
48-51. (canceled)
Dependencies are inferred from the claim text.